Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 115 Results

Title
Intervention Indication Therapeutic Area Year Actions
Acalabrutinib for chronic lymphocytic leukaemia – first line Acalabrutinib (Calquence; ACP-196) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2019 View  |  Download
Acalabrutinib for relapsed/refractory Chronic lymphocytic leukaemia Acalabrutinib (Calquence; ACP-196) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2019 View  |  Download
Acalabrutinib with bendamustine and rituximab for treating previously untreated mantle cell lymphoma Acalabrutinib (Calquence; ACP-196) , Bendamustine (Treanda; EP-3102; Levact; Ribomustin; bendamustine hydrochloride monohydrate; bendamustine hydrochloride) , Rituximab (MabThera; Rituxan; RG 105) Mantle cell lymphoma Haematological Cancer and Lymphomas 2022 View  |  Download
Asciminib for chronic myeloid leukaemia – chronic phase -third line Asciminib (ABL001) Chronic myeloid leukaemia (CML) Haematological Cancer and Lymphomas 2020 View  |  Download
ASTX727 for acute myeloid leukaemia ASTX727 Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2022 View  |  Download
Axicabtagene ciloleucel for relapsed/refractory diffuse large B-cell lymphoma – second-line Axicabtagene Ciloleucel (Yescarta; KTE-C19) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2019 View  |  Download
Axicabtagene ciloleucel for relapsed/refractory indolent non-Hodgkin lymphoma Axicabtagene Ciloleucel (Yescarta; KTE-C19) Non-Hodgkin lymphoma (NHL) Haematological Cancer and Lymphomas 2019 View  |  Download
Axicabtagene ciloleucel IV for relapsed/refractory acute lymphoblastic leukaemia in children and adolecents (aged 2-21 years) – second line Brexucabtagene autoleucel (Tecartus; KTE-X19) Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2017 View  |  Download
bb2121 for Relapsed and Refractory Multiple Myeloma Idecabtagene vicleucel (Ide-cel; bb2121) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Belantamab mafodotin for relapsed / refractory multiple myeloma – Fourth line Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2019 View  |  Download
1 2 3 11 12
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications